The addition of preoperative chemoradiation therapy to perioperative chemotherapy did not improve overall survival as compared with perioperative chemotherapy alone in patients with resectable gastric or gastroesophageal junction adenocarcinomas. The multi-continent, Phase III randomized TOPGEAR trial has definitively found no benefit from adding radiation before surgery in terms of overall or progression-free survival.

This clear finding was reported simultaneously in the New England Journal of Medicine and at the ESMO 2024 Congress held in Barcelona, Spain. After presenting the findings , first author Trevor Leong, MD, Radiation Oncologist at the Peter McCallum Cancer Centre in Melbourne, Australia, met up with Oncology Times reporter Peter Goodwin.